饮食与格列齐特对非胰岛素依赖型糖尿病患者止血系统的影响。
Effects of diet and gliclazide on the haemostatic system of non-insulin-dependent diabetics.
作者信息
Paton R C, Kernoff P B, Wales J K, McNicol G P
出版信息
Br Med J (Clin Res Ed). 1981 Oct 17;283(6298):1018-20. doi: 10.1136/bmj.283.6298.1018.
Abstract
The effect of the sulphonylurea gliclazide on tests of haemostatic function was studied in 14 newly diagnosed non-insulin-dependent diabetics. After two months' treatment with diet alone 11 of the 14 were given gliclazide; the three others remained on dietary treatment. Compared with pretreatment values, significant reductions in platelets retention, factor VIII-related antigen, factor VIII coagulant activity, and plasma heparin neutralising activity accompanied a fall in the plasma glucose concentration due to either diet alone or diet and gliclazide. The beneficial effects of gliclazide on platelet abnormalities seem likely to be due to its hypoglycaemic action rather than to any direct effect on haemostatic function.
摘要
在14例新诊断的非胰岛素依赖型糖尿病患者中研究了磺脲类药物格列齐特对止血功能测试的影响。在仅采用饮食治疗两个月后，14例患者中的11例给予格列齐特，另外3例继续进行饮食治疗。与治疗前的值相比，无论是单纯饮食治疗还是饮食加格列齐特治疗，随着血浆葡萄糖浓度的下降，血小板滞留、因子VIII相关抗原、因子VIII凝血活性和血浆肝素中和活性均显著降低。格列齐特对血小板异常的有益作用似乎可能是由于其降血糖作用，而非对止血功能的任何直接影响。
相似文献
1
Effects of diet and gliclazide on the haemostatic system of non-insulin-dependent diabetics.饮食与格列齐特对非胰岛素依赖型糖尿病患者止血系统的影响。
Br Med J (Clin Res Ed). 1981 Oct 17;283(6298):1018-20. doi: 10.1136/bmj.283.6298.1018.
2
Effects of the sulphonylurea drugs gliclazide and glibenclamide on blood glucose control and platelet function.磺脲类药物格列齐特和格列本脲对血糖控制及血小板功能的影响。
S Afr Med J. 1979 Aug 18;56(7):247-50.
3
Effect on platelet adhesiveness in diabetics after long-term treatment with a new oral hypoglycaemic agent, gliclazide.
Curr Med Res Opin. 1978;5(8):625-31. doi: 10.1185/03007997809110198.
4
Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus.格列齐特。对其药效学特性及在糖尿病治疗中的疗效的初步综述。
Drugs. 1984 Apr;27(4):301-27. doi: 10.2165/00003495-198427040-00002.
5
The effects of ingestion time of gliclazide in relationship to meals on plasma glucose, insulin and C-peptide levels.格列齐特与进餐相关的摄入时间对血糖、胰岛素和C肽水平的影响。
Eur J Clin Pharmacol. 1990;38(5):465-7. doi: 10.1007/BF02336685.
6
[Long-term effect of gliclazide on platelet function in diabetes].格列齐特对糖尿病患者血小板功能的长期影响
Zhonghua Yi Xue Za Zhi. 1984 Apr;64(4):233-5.
7
The effects of gliclazide on platelet function in patients with diabetes mellitus.
Curr Med Res Opin. 1982;8(3):200-3. doi: 10.1185/03007998209112384.
8
Long term improvement in insulin response with gliclazide treatment.
Diabete Metab. 1982 Dec;8(4):319-22.
9
[Medium term effect (3 months) of hypoglycemic sulfamide treatment (gliclazide) on insulin secretion of the non-insulin dependent diabetic].
Rev Med Interne. 1982 Dec;3(4):379-87. doi: 10.1016/s0248-8663(82)80048-9.
10
Effect of middle-term gliclazide treatment on insulin secretion in non-insulin dependent diabetics.中期格列齐特治疗对非胰岛素依赖型糖尿病患者胰岛素分泌的影响。
Curr Med Res Opin. 1984;9(1):56-63. doi: 10.1185/03007998409109560.
引用本文的文献
1
Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?磺脲类药物治疗患有心血管疾病的非胰岛素依赖型糖尿病患者：是福是祸？
Diabetologia. 1996 May;39(5):503-14. doi: 10.1007/BF00403296.
2
Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus.格列齐特。其药理特性及在非胰岛素依赖型糖尿病中治疗效果的最新情况
Drugs. 1993 Jul;46(1):92-125. doi: 10.2165/00003495-199346010-00007.
3
Oral hypoglycaemic agents.口服降糖药。
Br Med J (Clin Res Ed). 1983 May 14;286(6377):1564-7. doi: 10.1136/bmj.286.6377.1564.
4
Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus.格列齐特。对其药效学特性及在糖尿病治疗中的疗效的初步综述。
Drugs. 1984 Apr;27(4):301-27. doi: 10.2165/00003495-198427040-00002.
5
Adverse cardiovascular effects of sulphonylurea drugs. Clinical significance.磺脲类药物的心血管不良反应。临床意义。
Med Toxicol. 1987 May-Jun;2(3):190-209. doi: 10.1007/BF03259864.
6
Treatment of type II diabetes.II型糖尿病的治疗。
Br Med J (Clin Res Ed). 1986 Apr 19;292(6527):1033-4. doi: 10.1136/bmj.292.6527.1033.
7
Plasma t-PA and PAl-1 antigen concentrations in non-insulin dependent diabetic patients: effects of treatment modality on fibrinolysis.非胰岛素依赖型糖尿病患者血浆组织型纤溶酶原激活物（t-PA）和纤溶酶原激活物抑制剂-1（PAI-1）抗原浓度：治疗方式对纤溶的影响。
Korean J Intern Med. 1992 Jul;7(2):81-6. doi: 10.3904/kjim.1992.7.2.81.
本文引用的文献
1
A new method for the determination of fibrinogen in small samples of plasma.一种测定少量血浆样本中纤维蛋白原的新方法。
J Lab Clin Med. 1951 Feb;37(2):316-20.
2
3
Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. II. The significance, mechanism and consequences of defective fibrin polymerization.病理性血浆蛋白水解（“纤维蛋白溶解”）状态下凝血缺陷的发病机制。II. 纤维蛋白聚合缺陷的意义、机制及后果。
J Clin Invest. 1962 Apr;41(4):917-34. doi: 10.1172/JCI104547.
4
Hematologic alterations in diabetes mellitus.糖尿病中的血液学改变。
Am J Med. 1981 Feb;70(2):339-52. doi: 10.1016/0002-9343(81)90771-3.
5
Effect of metabolic control with insulin on plasma von Willebrand factor activity (VIIIR:WF) in diabetes mellitus.胰岛素代谢控制对糖尿病患者血浆血管性血友病因子活性（VIIIR:WF）的影响。
Thromb Res. 1980;17(1-2):261-6. doi: 10.1016/0049-3848(80)90313-8.
6
Haemostatic changes in diabetic coma.糖尿病昏迷中的止血变化。
Diabetologia. 1981 Sep;21(3):172-7. doi: 10.1007/BF00252650.
7
8
Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.在含有抗体的琼脂糖凝胶中通过电泳对蛋白质进行定量估计。
Anal Biochem. 1966 Apr;15(1):45-52. doi: 10.1016/0003-2697(66)90246-6.
9
Platelet factor 4(PF4) release during human platelet aggregation in diabetic patients.糖尿病患者人体血小板聚集过程中血小板第4因子（PF4）的释放
Thromb Diath Haemorrh. 1970 Oct 31;24(1):203-5.
10
Immunochemical quantitation of antigens by single radial immunodiffusion.通过单向辐射免疫扩散法对抗原进行免疫化学定量。
Immunochemistry. 1965 Sep;2(3):235-54. doi: 10.1016/0019-2791(65)90004-2.
Zotero 插件